Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbae684c01e866958496a909712f218d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541 |
filingDate |
2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c71f1b15d8b55340625616f55e1087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f725373382ddf2678efd98e33e8795d0 |
publicationDate |
2021-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2019330954-A1 |
titleOfInvention |
Neuroblastoma treatment with taurolidine hydrolysis products |
abstract |
Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically- resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals. |
priorityDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |